Haemonetics Corp (HAE)
92.13
+0.18
(+0.20%)
USD |
NYSE |
May 01, 16:00
92.17
+0.04
(+0.04%)
Pre-Market: 20:00
Haemonetics SG&A Expense (Quarterly): 111.71M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 111.71M |
September 30, 2023 | 104.90M |
June 30, 2023 | 93.48M |
March 31, 2023 | 97.76M |
December 31, 2022 | 94.66M |
September 30, 2022 | 92.03M |
June 30, 2022 | 92.23M |
March 31, 2022 | 92.42M |
December 31, 2021 | 80.73M |
September 30, 2021 | 75.78M |
June 30, 2021 | 91.22M |
March 31, 2021 | 83.71M |
December 31, 2020 | 65.64M |
September 30, 2020 | 63.57M |
June 30, 2020 | 62.30M |
March 31, 2020 | 52.83M |
December 31, 2019 | 78.27M |
September 30, 2019 | 77.92M |
June 30, 2019 | 73.00M |
March 31, 2019 | 53.80M |
December 31, 2018 | 73.88M |
September 30, 2018 | 77.25M |
June 30, 2018 | 68.54M |
March 31, 2018 | 79.02M |
December 31, 2017 | 97.86M |
Date | Value |
---|---|
September 30, 2017 | 72.78M |
June 30, 2017 | 66.86M |
March 31, 2017 | 71.70M |
December 31, 2016 | 71.40M |
September 30, 2016 | 71.12M |
June 30, 2016 | 87.50M |
March 31, 2016 | 76.28M |
December 31, 2015 | 78.94M |
September 30, 2015 | 74.56M |
June 30, 2015 | 87.61M |
March 31, 2015 | 77.78M |
December 31, 2014 | 82.51M |
September 30, 2014 | 84.77M |
June 30, 2014 | 92.56M |
March 31, 2014 | 88.10M |
December 31, 2013 | 89.56M |
September 30, 2013 | 81.51M |
June 30, 2013 | 106.81M |
March 31, 2013 | 87.62M |
December 31, 2012 | 86.78M |
September 30, 2012 | 81.03M |
June 30, 2012 | 67.62M |
March 31, 2012 | 65.04M |
December 31, 2011 | 61.38M |
September 30, 2011 | 62.61M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
52.83M
Minimum
Mar 2020
111.71M
Maximum
Dec 2023
83.38M
Average
83.71M
Median
Mar 2021
SG&A Expense (Quarterly) Benchmarks
Stryker Corp | 1.84B |
Boston Scientific Corp | 1.364B |
Insulet Corp | 212.80M |
Becton Dickinson & Co | 1.213B |
Masimo Corp | 159.90M |